Genentech Presents Longer-Term Efficacy and Safety for Enspryng in NMOSD

Genentech is presenting a range of new data from its neuroscience portfolio at the AAN 2022 Annual Meeting (April 2-7 in Seattle), including onger-term efficacy and safety for Enspryng in Neuromyelitis optica spectrum disorders (NMOSD) that reinforce previously seen results

Genentech will present encore long-term efficacy and safety data from the Enspryng SAkuraSky and SAkuraStar studies. These data reinforce the previously observed efficacy and safety of Enspryng, the first and only approved treatment designed to target and inhibit the IL-6 receptor activity and that can be administered subcutaneously every 4 weeks at home after training from a healthcare provider.

To increase the scientific understanding of NMOSD and improve care for all people living with the condition, Genentech has initiated SAkuraBONSAI, a multicenter, phase 3b, international study evaluating Enspryng treatment for people with AQP4-IgG seropositive NMOSD who are treatment naïve, or where prior rituximab (or biosimilar) treatment has failed. SAkuraBONSAI will further evaluate disease activity and progression using comprehensive imaging, biomarker and clinical assessment.